Why Moderna Stock Popped Today
Shares of Moderna (NASDAQ: MRNA) climbed 6.9% Wednesday after the biotechnology company said it expects to have a COVID-19 booster shot available -- as well as several new vaccine candidates in clinical trials -- later this year.
In late March, the National Institutes of Health (NIH) began a trial to evaluate an experimental vaccine from Moderna designed to defend against a worrisome coronavirus mutation first identified in South Africa. The goal is to develop booster shots to combat new virus variants that are resistant to Moderna's authorized COVID-19 vaccine.
"I want to make sure there are boost vaccines available in the fall so that we protect people as we go into the next fall and winter season in the U.S.," Moderna CEO Stephane Bancel told CNBC.
Source Fool.com
